Pharmaceutical News

RSS

Differing views on discount drug pricing

Medicare drug discount cards are now available for purchase. The US government estimates, the cards could save seniors as much as 25 percent of their prescription drug costs. According to a Harvard study

8 May 2004

Crime & prescription drug use in Australia

Research regarding the illicit use of prescription drugs in the Northern Territory and how this compares to other Australian states is the focus of the next presentation of Charles Darwin University’s Faculty of Education, Health and Science 2004 Seminar Program.

7 May 2004

West Nile treatment showing 100% response rate among immunocompetent patients

GenoMed, Inc. has announced that it will be limiting its treatment for West Nile virus encephalitis to immunocompetent patients only, where it has posted a 100% success rate.

7 May 2004

The world generic drug market is expected to grow 10-15% annually

Currently, the world generic drug market is approaching $40 billion. Over the next five years, the market is expected to grow 10-15% annually.

6 May 2004

Study shows Chromium Picolinate and Biotin Combination significantly lowers coronary risk factors in people with Type 2 Diabetes

Results of a new double-blind, placebo-controlled, randomized clinical study show that daily nutritional supplementation with a combination of chromium picolinate and biotin (marketed as Diachromeä) significantly improved coronary risk factors in people with type 2 diabetes.

6 May 2004

FRC applauds FDA for rejecting over-the-counter pill in America's pharmacies

Citing a concern that young teenagers may not safely use the morning after pill without a doctor's guidance, the Food and Drug Administration (FDA) late today officially rejected a plan to make the pill available over-the-counter in America's pharmacies. Family Research Council President Tony Perkins released the following statement in response to the FDA's decision:

6 May 2004

Vitrase has been approved for use as an adjunct to rehydrating agents

The Food and Drug Administration approved Vitrase (hyaluronidase for injection). Vitrase is an injectable drug approved as an adjunct to (in combination with) other injected drugs to increase their absorption and dispersion. Hyaluronidase has been used most commonly in combination with local anesthetics in the setting of ophthalmic (eye) surgery.

6 May 2004

Study finds malaria drug does not affect the ability of airline crew to perform their duties

Results from a new study presented today at the 75th Annual Scientific Meeting of the Aerospace Medical Association (AsMA) in Anchorage, USA, suggest that MalaroneTM (atovaquone and proguanil hydrochloride) would not be expected to affect the ability of pilots and cabin crew to perform their duties while on an aircraft.

6 May 2004

Experimental sleep drug eszopiclone helps elderly to sleep better

Older people with insomnia slept better and longer after taking an experimental sleep medication, according to research at Wake Forest University Baptist Medical Center.

6 May 2004

New guidelines for using new antiepileptic drugs to treat epilepsy

The number of drugs available to treat epilepsy have more than doubled in the last decade. The American Academy of Neurology and the American Epilepsy Society have assembled the top experts in the field to evaluate the available data of 1,462 research articles in order to create a guideline for the treatment of epilepsy with the new antiepileptic drugs (AEDs).

6 May 2004

Ritalin drug used to treat hyperactive children boosts the potency of Parkinson's drug levodopa

A well-known drug used to treat hyperactive children boosts the potency of another drug that reduces Parkinson's disease symptoms, an Oregon Health & Science University study has found.

6 May 2004

Medicare says drug discount program shows savings up to 17 percent for brand name drugs

The first analysis comparing the Medicare-approved drug discount cards with the current prices for prescription medicines shows savings of at least 10 to 17 percent for brand name drugs and far larger savings for generic drugs

6 May 2004

FDA approval of Hylaform and Restylane, both injectable gels, to treat facial wrinkles

The list of cosmetic soft tissue fillers on the market and in the pipeline worldwide is growing rapidly. Many have been introduced with great fanfare; relatively few stand the test of regulatory or peer review - as well as the test of time.

6 May 2004

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Immtech International, Inc. announced today that it signed an agreement with CombinatoRx of Boston, Massachusetts to screen its lead aromatic cationic compounds, DB289 and DB75, for activity against various cancers.

5 May 2004

Trial of antibody for HIV Infection

Tanox, Inc. announced today that it has begun dosing patients in its Phase 2 clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV).

5 May 2004

Agreement expands Quintiles capabilities to support drug approvals in Japan

Quintiles Transnational Corp. today announced an agreement to conduct clinical trials in Peru involving ethnic Japanese, further expanding the company's ability to support new drug applications in Japan.

5 May 2004

Mylan announces FDA approval of Parkinson’s disease drug

The FDA approval clears the way for Bertek to market APOKYN and provides a new therapy for “off” episodes, one of the most debilitating aspects suffered by patients with Parkinson’s disease.

5 May 2004

First canine insulin drug

FDA has approved a porcine insulin zinc suspension product as the first drug for treating diabetic dogs. Prior to the development of this product, the only treatment veterinarians could use on diabetic dogs was human insulin, which is less compatible with a dog’s metabolic system.

4 May 2004

UK researchers get 180,000 Euros to identify and develop new vaccines against Tuberculosis

A researcher from Birmingham University's School of Biosciences has won EU funding of 180,000 Euros to identify and develop new vaccines against Tuberculosis.

4 May 2004

New license agreement for rotavirus diarrhea vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today a new license agreement aimed at helping to prevent hundreds of thousands of deaths annually from rotavirus diarrhea in children living in developing countries.

4 May 2004